These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27736841)

  • 21. Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling.
    Gao F; Wang FG; Liu RR; Xue F; Zhang J; Xu GQ; Bi JH; Meng Z; Huo R
    Int J Oncol; 2017 May; 50(5):1821-1831. PubMed ID: 28393235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines.
    Ungar S; Van de Meeren A; Tammilehto L; Linnainmaa K; Mattson K; Gerwin BI
    Br J Cancer; 1996 Nov; 74(10):1534-40. PubMed ID: 8932331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
    Urso L; Calabrese F; Favaretto A; Conte P; Pasello G
    Crit Rev Oncol Hematol; 2016 Jan; 97():220-30. PubMed ID: 26358421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles.
    Yu H; Zou Y; Jiang L; Yin Q; He X; Chen L; Zhang Z; Gu W; Li Y
    Biomaterials; 2013 Apr; 34(11):2738-47. PubMed ID: 23352573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
    Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
    Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRIM47 silencing inhibits the malignant biological behaviors of prostate cancer cells by regulating MDM2/p53 signaling.
    Wang C; Chang R; Li J; Li L
    Cell Biochem Biophys; 2024 Jun; 82(2):1567-1578. PubMed ID: 38802602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-26a targets the mdm2/p53 loop directly in response to liver regeneration.
    Zhou J; Li Z; Huang Y; Ju W; Wang D; Zhu X; He X
    Int J Mol Med; 2019 Oct; 44(4):1505-1514. PubMed ID: 31364731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LATS2 is a tumor suppressor gene of malignant mesothelioma.
    Murakami H; Mizuno T; Taniguchi T; Fujii M; Ishiguro F; Fukui T; Akatsuka S; Horio Y; Hida T; Kondo Y; Toyokuni S; Osada H; Sekido Y
    Cancer Res; 2011 Feb; 71(3):873-83. PubMed ID: 21245096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
    Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
    Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
    Giono LE; Manfredi JJ
    Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
    Drummond CJ; Esfandiari A; Liu J; Lu X; Hutton C; Jackson J; Bennaceur K; Xu Q; Makimanejavali AR; Del Bello F; Piergentili A; Newell DR; Hardcastle IR; Griffin RJ; Lunec J
    Oncotarget; 2016 Jul; 7(29):46203-46218. PubMed ID: 27323823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival.
    Liu T; Zhang H; Xiong J; Yi S; Gu L; Zhou M
    Mol Cancer; 2015 Mar; 14():65. PubMed ID: 25888903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional role of RRS1 in breast cancer cell proliferation.
    Song J; Ma Z; Hua Y; Xu J; Li N; Ju C; Hou L
    J Cell Mol Med; 2018 Dec; 22(12):6304-6313. PubMed ID: 30320499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.
    Segers K; Backhovens H; Singh SK; De Voecht J; Ramael M; Van Broeckhoven C; Van Marck E
    Virchows Arch; 1995; 427(4):431-6. PubMed ID: 8548129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.